NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 146 filers reported holding NEKTAR THERAPEUTICS in Q3 2014. The put-call ratio across all filers is 0.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2014 | $318,000 | -25.9% | 26,371 | -21.1% | 0.00% | – |
| Q2 2014 | $429,000 | -58.8% | 33,441 | -61.1% | 0.00% | -100.0% |
| Q1 2014 | $1,042,000 | -44.2% | 85,950 | -47.8% | 0.00% | -50.0% |
| Q4 2013 | $1,868,000 | +149.4% | 164,558 | +129.3% | 0.00% | +100.0% |
| Q3 2013 | $749,000 | +67.2% | 71,754 | +85.2% | 0.00% | 0.0% |
| Q2 2013 | $448,000 | – | 38,746 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |